Reported Standalone quarterly numbers for Jagsonpal Pharmaceuticals are:Net Sales at Rs 60.14 crore in December 2022 up 10.4% from Rs. 54.47 crore in December 2021.
Quarterly Net Profit at Rs. 7.78 crore in December 2022 up 43.99% from Rs. 5.41 crore in December 2021.
EBITDA stands at Rs. 10.37 crore in December 2022 up 37.17% from Rs. 7.56 crore in December 2021.
JagsonpalPharma EPS has increased to Rs. 2.97 in December 2022 from Rs. 2.06 in December 2021.
| JagsonpalPharma shares closed at 301.80 on March 13, 2023 (NSE) and has given -21.67% returns over the last 6 months and 22.29% over the last 12 months. |
| Jagsonpal Pharmaceuticals | | Standalone Quarterly Results | in Rs. Cr. |
|
| Dec'22 | Sep'22 | Dec'21 | | Net Sales/Income from operations | 60.14 | 60.53 | 54.47 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 60.14 | 60.53 | 54.47 | | EXPENDITURE | | Consumption of Raw Materials | 6.12 | 7.59 | 15.68 | | Purchase of Traded Goods | 15.46 | 10.96 | 13.36 | | Increase/Decrease in Stocks | 1.25 | 2.39 | -7.31 | | Power & Fuel | -- | -- | -- | | Employees Cost | 14.20 | 14.98 | 15.13 | | Depreciation | 0.33 | 0.20 | 0.37 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 14.47 | 11.70 | 12.00 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 8.30 | 12.70 | 5.24 | | Other Income | 1.74 | 1.12 | 1.95 | | P/L Before Int., Excpt. Items & Tax | 10.04 | 13.82 | 7.19 | | Interest | 0.18 | 0.03 | 0.06 | | P/L Before Exceptional Items & Tax | 9.87 | 13.79 | 7.14 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 9.87 | 13.79 | 7.14 | | Tax | 2.08 | 3.38 | 1.73 | | P/L After Tax from Ordinary Activities | 7.78 | 10.41 | 5.41 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 7.78 | 10.41 | 5.41 | | Equity Share Capital | 13.10 | 13.10 | 13.10 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 2.97 | 3.97 | 2.06 | | Diluted EPS | 2.97 | 3.97 | 2.06 | | EPS After Extra Ordinary | | Basic EPS | 2.97 | 3.97 | 2.06 | | Diluted EPS | 2.97 | 3.97 | 2.06 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|